Google has invested in Navigenics, hoping to broaden its reach to include genetic information, say this Business Week article. As the media sees it, Navigenics is hoping to pull away from 23andMe (which Google also invested in). "23andMe has taken the approach of providing you a fun, social, and ancestral look at your DNA," says Amy DuRoss, head of policy and business affairs for Navigenics, whereas her company "has taken the v

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.